Efficiency in the biopharmaceutical space has never been more top-of-mind. The COVID-19 pandemic brought an unprecedented urgency to R&D and the key players delivered: Several groups produced a vaccine in record time. To maintain and improve on this...
2020 has been an eventful year: but 2021 will also require skilful navigation. Here's some of the people who are stepping up to leading roles as we head into a new year.
COVID-19 is like a big oak tree casting shade on all other biopharma industry developments. Vaccine-related articles dominate the most popular story rankings. With Pfizer and BioNTech now out in front in the coronavirus vaccine race, we track the related...
The gene therapy space is a rapidly developing areas in the industry, as a result those with expertise are finding their knowledge is invaluable to companies looking to advance in the space.
As we have entered the summer, companies have taken to refreshing their leadership positions, including at companies such as Gilead, Alnylam, and Maze Therapeutics.
BMS’ capture of Celgene caught much attention, due to the size and scale of the acqusition, but rival companies have taken the chance to snap up employees that have left after the deal.
As we enter spring, several companies have refreshed the look of their executive boards – some to strengthen their direction and some out of necessity.
While last month saw many pharma executives leaving their positions to head towards smaller biotech companies, this month saw members of the industry climbing the ladder from various different starting points.
In a significant move at the larger end of the biopharma world, AstraZeneca’s global VP of cardiovascular, renal and metabolism made the move to Novo Nordisk to head up its biopharm unit.
As the stream of executives flowing from large pharma companies to smaller biotechs builds into a torrent, another month has passed with a number of significant switches. Notably, two former Genentech employees, responsible for work on some of its bestselling...
Ambition, hard work and a focus on quality has made Celltrion the ‘pioneers of the mAb biosimilar industry,’ the firm told Biopharma-Reporter during a tour of its biomanufacturing site in Songdo, Korea.
Senior Scientist at Pfizer? Head of Upstream Development at GSK? How about working at B-MS’s expanding facility in Massachusetts? Time to dust off those CVs and check out the latest biopharma jobs.
Former Secretary of State and First Lady Hillary Clinton popped in for a long interview during one of the keynote luncheons to discuss all sorts of different topics with a BIO executive. The luncheon nicely complimented the international theme of the...
A government funded bioprocessing institute is helping to drive biopharma investment and retrain workers in Ireland, and Biopharma-Reporter.com visited to find out what happens in this "flight simulator for biopharma manufacturing."
Outdated technology is one of the greatest challenges in creating next-generation biodrugs, says Jonathan Robinson, who is leading the development of a £38m ($63m) national biomanufacturing hub in the UK.
Lab rats are not the only animals to play a role in bologics development as Biopharma-Reporter.com discovered when it donned its wellington boots and took a wonder down to the pharm...
Last year Octapharma filed the world’s first ‘truly human’ recombinant Factor VIII clotting protein for EMA review and invited BioPharma-Reporter.com to visit the Swedish site where it makes the haemophilia treatment using HEK cells.
With more and more biopharmaceutical firms developing therapeutic antibodies public knowledge of these powerful molecules is increasing, which is good news given how badly they've been portrayed in films so far.
Aesica's new Technical Director talks CMO flexibility and Catalent appoints new delivery unit head - welcome to Outsourcing-Pharma's People on the Move.
BMS have appointed a new director and ex Shire-CEO joins Questcor - yes, you've guessed it, it's in-Pharmatechnologist.com's weekly pharma people round-up.
